Pharmaceutical industry – Page 35
-
NewsPfizer’s response to compound fraud spotlights quality issues
‘Bosutinib isomer’ typifies threat posed by evolution of chemical supply chain
-
BusinessPfizer and Allergan agree mega-merger
$160 billion deal allows Pfizer to escape US tax system by re-homing in Ireland
-
Business
Drug firms to share chemical compound libraries
AstraZeneca and Sanofi aim to facilitate drug discovery by swapping 210,000 proprietary chemical compounds
-
Opinion
Toeing the advertising line
Companies have to tread a little carefully when it comes to advertising prescription drugs
-
BusinessViral cancer therapy approved in the US
T-Vec is the first approved oncolytic virus, but its limited treatment scope means it is unlikely to become a blockbuster
-
BusinessPharma kickback claims lead to individual prosecutions
Warner Chilcott and Novartis face large fines for paying doctors to prescribe their drugs
-
Business
AstraZeneca to buy ZS Pharma for ion-balance drugs
$2.7 billion deal anticipates regulatory success for drug candidate under review
-
Business
Samsung to sell chemicals businesses to Lotte
Korean conglomerate Lotte will pay £1.7 billion for stake in Samsung’s chemicals businesses
-
Business
Shire to buy rare disease specialist Dyax
Deal includes an already-approved drug for angioedema and an experimental antibody treatment
-
Business
Bristol-Myers Squibb to buy Cardioxyl for heart drug
Deal worth up to $2bn gives BMS full rights to Phase II clinical candidate
-
NewsMalaria vaccine pilot studies recommended by WHO
GlaxoSmithKline’s RTS,S vaccine must undergo further testing before being rolled out, says World Health Organization panel
-
Business
Biogen to cut 800 jobs worldwide
US biotech is reducing its workforce by 11% and cancelling several R&D programmes to cut costs
-
Business
BMS agrees $1.7bn immuno-oncology collaboration
Deal strengthens cancer antibody alliance with Five Prime Therapeutics
-
Business
Bristol-Myers Squibb fined for alleged Chinese bribes
US Securities and Exchange Commission accepts $14m settlement for charges covering the last five years
-
Opinion
Human capital
Business leader: Incubators and hubs for small and medium-sized enterprises are all the fashion
-
OpinionWhat the market will bear?
Martin Shkreli’s monopolising model poses some uncomfortable questions for the pharma industry, says Derek Lowe
-
OpinionSpice up your compounds
An occasional foray into uncharted territory is the hot sauce of medicinal chemistry, says Derek Lowe
-
Business
Amgen expands cardiovascular portfolio with Dezima acquisition
Amgen’s $300 million purchase of Dutch biotech gives the company the potential to offer more varied treatment options to lower cholesterol
-
BusinessMerger fever sweeps pharma
The life sciences sector has been gripped by a mergers and acquisition frenzy, and it looks set to continue. But what does it mean for the industry?